ÂÜÀòÂÒÂ×

Sam is the president of Agilent's Diagnostics and Genomics Group. He is responsible for overall strategy, along with business and financial results, for the group which includes the pathology, genomics, companion diagnostics, and Nucleic Acid Solutions (therapeutic oligonucleotides) businesses.

Sam returned to Agilent in early 2017 to lead the Strategy and Corporate Development function. He led the creation of Agilent's first long range strategy while strengthening Agilent's M&A capabilities, overseeing numerous acquisitions that strategically enhanced Agilent's offerings to customers.

Prior to re-joining Agilent, Sam was vice president of global marketing at Illumina, a San Diego-based life sciences company. He was responsible for leading the overall marketing function for Illumina including product management, clinical marketing, and corporate marketing. He was an integral part of defining a multi-year sequencing platform road-map and successfully launched several sequencing systems and consumables to drive market defining growth.

Prior to his years at Illumina, Sam was vice president and general manager of the genomic assays business unit at Life Technologies, with P&L responsibility for the TaqManâ„¢ franchise and next generation qPCR instruments and solutions.

Earlier in his Agilent career, Sam was vice president and general manager of the Americas with responsibility for sales, regional marketing, and customer and applications support for the Life Sciences and Chemical Analysis Group.

Sam earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley.